HYTRIN

This brand name is authorized in Ecuador, Hong Kong SAR China, Ireland, Israel, Netherlands, Poland, Singapore, Turkey, UK.

Active ingredients

The drug HYTRIN contains one active pharmaceutical ingredient (API):

1	Terazosin UNII D32S14F082 - TERAZOSIN HYDROCHLORIDE
	Although the exact mechanism of the hypotensive action is not established, the relaxation of peripheral blood vessels appears to be produced mainly by competitive antagonism of post-synaptic alpha-adrenoceptors. Terazosin usually produces an initial gradual decrease in blood pressure followed by a sustained antihypertensive action.
	Read more about Terazosin

Medication package inserts

Below package inserts are available for further reading:

Document	Type	Information Source
HYTRIN Tablet	MPI, EU: SmPC	Medicines & Healthcare Products Regulatory Agency (GB)

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
G04CA03	Terazosin	G Genito urinary system and sex hormones → G04 Urologicals → G04C Drugs used in benign prostatic hypertrophy → G04CA Alpha-adrenoreceptor antagonists
Discover more medicines within G04CA03

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
EC	Agencia Nacional de Regulación, Control y Vigilancia Sanitaria	25.198-06-03, 25.199-06-03
GB	Medicines & Healthcare Products Regulatory Agency	31479, 31512, 31554, 39025, 39027, 39030, 39573, 39576, 39579
HK	Department of Health Drug Office	28970, 28971, 28972
IE	Health Products Regulatory Authority	27596, 27650, 27669, 27707, 27825, 27837, 27841
IL	מִשְׂרַד הַבְּרִיאוּת	3364, 3380
NL	Z-Index G-Standaard, PRK	36706, 37435, 45268
PL	Rejestru Produktów Leczniczych	100080131, 100081142, 100081159
SG	Health Sciences Authority	11674P, 11675P, 11676P
TR	İlaç ve Tıbbi Cihaz Kurumu	8699548010491, 8699548010774, 8699548011146